Sanofi Taps Fox Foundation For Parkinson’s Drug Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi and the Michael J. Fox Foundation have teamed up on the development of a treatment for cognitive deficits related to Parkinson’s disease.
You may also be interested in...
FDA Should Create “Clearly Articulated Pathway” For Patient-Centered Research – Pfizer’s Lewis-Hall
Pfizer CMO Freda Lewis-Hall acknowledged FDA’s current activities to promote patient-centered research, but called on the agency to lead in developing guidance to help industry be more proactive in incorporating patients into its research.
Disease Foundations Are Finding Their Way In New Research Relationships
Disease foundations have realized that funding basic research is not enough to serve their patient groups, but forging those later-stage relationships can be tricky and all parties involved are developing new flexibilities, panelists at the BIO annual meeting said June 21 in Boston.
Positive Early Results For Addex Parkinson’s Drug Dipraglurant Spur Hopes For Deal
In a small, short Phase IIa study, an oral inhibitor of mGluR5 proved effective at reducing dyskinesia caused by levodopa. If future trials are positive, the drug would have a significant positive impact on Parkinson’s patients, says the Michael J. Fox Foundation.